Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema.

NCT01571232 is registered in ClinicalTrials.gov with Retina Macula Institute as lead sponsor.

NCT NCT01571232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01571232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema.
Lead sponsor
Retina Macula Institute
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2012
Completion date
March 31, 2015
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema, non-proliferative diabetic retinopathy, proliferative diabetic retinopathy